Latest / Stock Movers / ASML Rises, Orsted Drops, Galderma Slips
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio.
- 0:06Speaker 2: News.
- 0:08Speaker 1: The Stock Movers Report. Your roundup of companies making moves
- 0:12Speaker 1: in the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 2: Let's take a look at some of the stocks on
- 0:18Speaker 2: the move today in Europe now. I'm Tiwa Adebayo alongside
- 0:21Speaker 2: Caroline Hebker, and we're joined by Bloomberg's breaking news editor,
- 0:25Speaker 2: Louise Moon. Now, Louise, we've got possibly Europe's most AI-adjacent giant, ASML,
- 0:30Speaker 2: has earnings out today.
- 0:32Speaker 1: How is it doing?
- 0:34Speaker 3: Shares are rising up about 3.5% in morning trading on
- 0:37Speaker 3: the back of those. As you say, it was their results,
- 0:39Speaker 3: their third quarter results. So, record high gross margin, a
- 0:42Speaker 3: higher full-year outlook. Essentially, demand is very strong. So, they're
- 0:48Speaker 3: saying that their current supply won't be able to fully
- 0:50Speaker 3: meet demand in 2027 and 2028. So, they're looking for
- 0:54Speaker 3: ways to produce more chipmaking machines over the next two years.
- 0:59Speaker 3: And their new target, they're going to give a new
- 1:01Speaker 3: target that is beyond one that they gave relatively recently. So,
- 1:05Speaker 3: soaring demand, essentially. Obviously, this comes with the wider backdrop
- 1:09Speaker 3: of more recently people have been questioning if the AI
- 1:12Speaker 3: boom is sustainable. So, these results potentially showing a bit
- 1:15Speaker 3: of a window into chipmakers' plans. ASML have got quite
- 1:18Speaker 3: a long lead time. So, it's a lead time of
- 1:20Speaker 3: about over a year between order and delivery. So, that
- 1:23Speaker 3: demand is really showing what's happening in the AI space
- 1:27Speaker 3: and shares rising there, as I say, about almost 4%.
- 1:29Speaker 4: Yeah. Nice problem to have, isn't it? It's the only
- 1:32Speaker 4: company in the world that's making these cutting-edge lithography machines
- 1:36Speaker 4: that you need, obviously, to make the semiconductors to deliver
- 1:39Speaker 4: the AI. Now, in terms of other stories, Orsted stuck
- 1:46Speaker 4: in this ongoing saga with the White House.
- 1:48Speaker 2: Yes.
- 1:48Speaker 4: Indeed.
- 1:49Speaker 3: And the latest being that the Justice Department in the U.S.
- 1:52Speaker 3: has asked the federal court to re-evaluate quite a key
- 1:55Speaker 3: permit for one of their offshore wind farms.
- 1:57Speaker 4: That's off Rhode Island.
- 1:59Speaker 3: It began producing power in March, but now they're wanting
- 2:02Speaker 3: it to re-evaluate the permit, make sure it's in compliance
- 2:05Speaker 3: with with a federal law. So, essentially, it could be
- 2:09Speaker 3: quite a big setback. As you say, it comes after
- 2:14Speaker 3: quite a lot of hurdles for Orsted and the sector
- 2:18Speaker 3: in the U.S. under the Trump administration. There'd been an
- 2:21Speaker 3: agreement in September to reform the U.S. system in terms
- 2:25Speaker 3: of approving infrastructure products, and therefore, there was hope of
- 2:29Speaker 3: less hurdles. That included some assurances from the Trump administration
- 2:33Speaker 3: to stop blocking some wind and solar developments that had permits.
- 2:38Speaker 3: But this is the latest potential hurdle. Obviously, it could
- 2:42Speaker 3: add regulatory execution risk. An analyst in Barclays saying, you know,
- 2:49Speaker 3: it sees the potential for impairment at their third quarter results. So,
- 2:53Speaker 3: shares unsurprisingly dropping over about 4% on the back of this.
- 2:58Speaker 2: Okay, that's the latest from Allstead. But looking to cosmetics now,
- 3:03Speaker 2: and the skincare company Galderma looking to grow a new
- 3:06Speaker 2: layer of its business.
- 3:07Speaker 3: Indeed, yeah. They've bought a California-based company called Zoskin Health.
- 3:11Speaker 3: That's from Blackstone for about US $ 1. 5 billion. It's an
- 3:15Speaker 3: all-cash deal. And essentially, it's Galderma. So, Galderma is based
- 3:19Speaker 3: in Switzerland, the dermatology firm. Essentially, it's them pushing into
- 3:23Speaker 3: two things. One, medical-grade skincare, which is quite a fast-growing segment.
- 3:27Speaker 3: And two, further into the US. So, they're expanding their
- 3:30Speaker 3: US skincare portfolio. And the CEO actually said that the
- 3:33Speaker 3: US … will at some point soon probably account for
- 3:37Speaker 3: the majority of their sales. Shares, however, down about 1.5%
- 3:41Speaker 3: in morning trading. Analysts are saying that, yes, it's a
- 3:44Speaker 3: good fit. It's attractive. It's a fast-growing segment. But the
- 3:47Speaker 3: multiple is fairly high. And that's what's dragging shares slightly
- 3:51Speaker 3: lower there.
- 3:52Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:56Speaker 1: us throughout the day for the latest roundup of companies
- 3:59Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:03Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:08Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:11Speaker 1: Business app.